… 30 treatment arms, including 22 arms for the gefitinib group and 8 arms for the erlotinib group.
Both RR and DCR strongly correlated with median survival time (MST; p < 0.0001 and p = …

… : We investigated survival potential in patients receiving erlotinib after failure of gefitinib, …
patients who received erlotinib after experiencing progression with gefitinib. Our primary …

Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor tyrosine
… Gefitinib and erlotinib demonstrated comparable effects on progression‐free survival (…

… We assumed that gefitinib and erlotinib in the experimental … in this meta-analysis of gefitinib
and erlotinib as most of the … significantly differ between gefitinib or erlotinib vs chemotherapy …

… of long-term exposure to gefitinib or erlotinib that … with gefitinib or erlotinib. The aim of the
study was to correlate clinical response to gefitinib or erlotinib, time to progression, and survival …

… erlotinib following gefitinib failure, patients who showed prolonged PFS with gefitinib benefit
from erlotinib. … As a first-line treatment, gefitinib exhibits a median progression-free survival (…

… of pemetrexed significantly improved the overall survival (OS) in … survival (PFS) and overall
survival (OS) with maintenance … with EGFR TKIs (gefitinib and erlotinib) produces a significant …

… Our study revealed the obvious disparity in drug selection between erlotinib and gefitinib in
… Gefitinib and erlotinib did not lead to different overall survival in patients with mutant EGFR. …

… Erlotinib monotherapy is an effective treatment that can prolong survival for patients with …
Although a significant survival benefit has not been demonstrated for gefitinib in a placebo-…

… Our results showing that EGFR mutation and smoking status can function as predictors of
survival benefit differ from reports on erlotinib. However, they concur with reports to date on …